Borenius advised Danske Bank as the sole bookrunner on Bioretec’s directed share issue

We advised Danske Bank A/S, Finland Branch, as the sole bookrunner on Bioretec Ltd’s EUR 6 million directed share issue through an accelerated bookbuilding procedure.

Bioretec successfully completed the share issue on 27 November 2024. The significantly oversubscribed placing to long-only institutional investors was carried out based on offers received in an accelerated bookbuilding procedure.

Bioretec is a globally operating Finnish medical device company that continues to pioneer the application of biodegradable orthopaedic implants. The products developed and manufactured by Bioretec are used worldwide in approximately 40 countries. Bioretec’s shares are listed on the Nasdaq First North Growth Market Finland.